Domů › Kolorektální karcinom › Connecticut › New Haven
Klinické studie Kolorektální karcinom v New Haven, CT
20 studií pro Kolorektální karcinom hledá účastníky v lokalitách v New Haven a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Probíhá náborFáze 3
- Yale University School of Medicine /ID# 279373, New Haven
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- Yale Cancer Center, New Haven
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Probíhá náborFáze 1
- Exelixis Clinical Site #62, New Haven
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Probíhá náborFáze 1/2
- Yale University School of Medicine, New Haven
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Probíhá náborFáze 1
- Yale Cancer Center, New Haven
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Probíhá náborFáze 2
- Yale New Haven Hospital /ID# 270565, New Haven
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Probíhá náborFáze 3
- Yale University School Of Medicine, New Haven
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Probíhá náborFáze 1/2
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Probíhá náborFáze 1
- Yale Cancer Center, New Haven
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Probíhá náborFáze 1/2
- Yale University School of Medicine - Yale Cancer Center, New Haven
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Probíhá náborFáze 1
- Yale Cancer Center, New Haven
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Probíhá náborFáze 3
- Clinical Study Site, New Haven
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Probíhá náborFáze 2
- Yale University, New Haven
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Yale University School of Medicine, New Haven
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Probíhá náborFáze 1/2
- Yale University, New Haven
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Probíhá náborFáze 1/2
- Yale Comprehensive Cancer Center, New Haven
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Probíhá náborFáze 1/2
- Yale University, New Haven
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Probíhá náborFáze 1
- Smilow Cancer Hospital (Yale University), New Haven
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Probíhá náborFáze 1
- Yale University, New Haven
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Probíhá náborFáze 1/2
- Yale University, Yale Cancer Center, New Haven
Studie Kolorektální karcinom v jiných městech
- Houston, TX102 studií
- New York City, NY78 studií
- Nashville, TN69 studií
- Boston, MA63 studií
- Los Angeles, CA59 studií
- Arlington, VA52 studií
- St. Louis, MO50 studií
- San Antonio, TX46 studií
- Philadelphia, PA44 studií
- Grand Rapids, MI40 studií
- Baldwin Park, CA37 studií
- Chicago, IL34 studií
Další studie v New Haven
- Nemalobuněčný plicní karcinom41 studií
- Rakovina prsu38 studií
- Rakovina (všechny typy)33 studií
- Metastatický karcinom23 studií
- Rakovina plic22 studií
- Squamózní buněčný karcinom hlavy a krku22 studií
- Rakovina vaječníků21 studií
- Rakovina prostaty20 studií
- Akutní myeloidní leukemie17 studií
- Porucha užívání alkoholu (AUD)17 studií
- Předávkování opioidy17 studií
- Rakovina slinivky břišní16 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.